Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986116 | 0.89 | GNAI3 (0.45) | GNAI3GNAO1GNAI1TERTDPP7 | |
| SCHEMBL32679434 | 0.87 | GNAI3 (0.47) | GNAI3GNAO1GNAI1TERTDPP7 | |
| SCHEMBL30903264 | 0.85 | GNAI3 (0.44) | GNAI3GNAO1GNAI1 | |
| SCHEMBL30306242 | 0.85 | TERT (0.52) | GNAI3GNAO1GNAI1TERTDPP7 | |
| SCHEMBL30445693 | 0.85 | TERT (0.52) | GNAI3GNAO1GNAI1TERTDPP7 | |
| SCHEMBL30379876 | 0.85 | TERT (0.52) | GNAI3GNAO1GNAI1TERTDPP7 | |
| SCHEMBL10789443 | 0.85 | TERT (0.52) | GNAI3GNAO1GNAI1TERTDPP7 | |
| SCHEMBL10789429 | 0.85 | TERT (0.52) | GNAI3GNAO1GNAI1TERTDPP7 | |
| SCHEMBL32679433 | 0.84 | DPP8 (0.41) | GNAI3GNAO1GNAI1TERTDPP7 | |
| SCHEMBL31063887 | 0.83 | GNAI3 (0.44) | GNAI3GNAO1GNAI1TERTDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073446-A1 | Antigen Delivery Vectors and Constructs | ALTIMMUNE UK LIMITED (GB) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073446-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | GNAI3 2114/4885GNAO1 4141/4885GNAI1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.